Clovis Oncology benefited from a lot of good news last month.
News & Analysis: Clovis Oncology
The stock price is soaring. Are investors getting ahead of themselves by speculating on a potential acquisition?
These three names could soar early in 2020.
A $9.7 billion deal and two failed takeover bids ushered in renewed enthusiasm for acquisitions in the pharmaceutical industry. What makes these stocks buyout candidates?
These dirt cheap healthcare stocks could be poised for a major upswing in 2020.
CLVS earnings call for the period ending September 30, 2019.
With stock valuations down and out, the timing may be ripe for pharma and big biotech companies to start bargain hunting.
These three beaten-down cancer stocks could prove to be amazing value plays.
Wall Street is questioning the value and purpose of a recent deal.
Investors need ongoing clinical trials to deliver -- and for the business to rein in expenses.